News
Paroxysmal Abnormalities in the Brain and Defining the ‘Seizure’: Michael Sperling, MD
January 23rd 2023At the 2022 AES Conference, the Baldwin Keyes professor of neurology at Thomas Jefferson University, talked about what defines a ‘seizure’ and changing the terminology. [WATCH TIME: 5 minutes]
Growing Brivaracetam’s Potential Through the Adaptive, Dose-Finding EXPAND Study
January 22nd 2023The trial’s 2-stage design seeks to answer questions about the dosing and efficacy of brivaracetam, a previously approved agent for partial-onset seizures in patients with childhood absence epilepsy and juvenile absence epilepsy.
Aβ Protofibril Elimination in Alzheimer Disease
January 21st 2023One model of AD suggests that Aβ pathophysiology triggers downstream molecular pathways, including tauopathy, which lead to cortical neurodegeneration, and cognitive decline is further attributed to the associated neurocortical Aβ plaques.
Weighing Epilepsy Surgery as a Potential Treatment Option for Patients: Scott Perry, MD
January 20th 2023At the 2022 AES Conference, the head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center, talked about epilepsy surgery as an alternative for some patients. [WATCH TIME: 5 minutes]
Building Trust in the Epilepsy Clinician-Patient Relationship: Elizabeth Felton, MD, PhD
January 20th 2023The assistant professor in the Department of Neurology at the University of Wisconsin spoke about healthcare providers establishing trust with their patients and improving health equity. [WATCH TIME: 3 minutes]
Real-World Data of Spinal Muscular Atrophy Shows High Adherence to Nusinersen Dosing Regimen
January 20th 2023Nearly 94% of nusinersen doses recorded in electronic health records database and more than 80% of doses recorded in the claims databases were received on time according to the recommended dosing schedule.
Ticagrelor and Aspirin Combination Most Effective in CYP2C19 Carriers With Low Risk Profile
January 19th 2023The study provided class II evidence that CYP2C19 loss of function carriers with minor stroke or transient ischemic attack at low risk, but not high risk, of recurrent stroke received greater benefit from ticagrelor and aspirin rather than clopidogrel and aspirin.
Striving for Health Equity in Epilepsy Care: Elizabeth Felton, MD, PhD
January 19th 2023At the 2022 AES annual meeting, the assistant professor in the Department of Neurology at the University of Wisconsin talked about her presentation and the key actions for addressing health equity. [WATCH TIME: 4 minutes]
Post-Stroke Seizure Predictive Models, SeLECT Model: Carolina Ferreira Atuesta, MD, MSc
January 18th 2023The scientific researcher and clinical manager, Icahn School of Medicine at Mount Sinai, spoke about the clinical models used to predict seizures in poststroke patients. [WATCH TIME: 4 minutes]
Influence of Antiepileptic Medications on Seizure Frequency in Insomnia: Milena Pavlova, MD
January 18th 2023At the 2022 AES annual meeting, the associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital talked about seizure frequency and insomnia. [WATCH TIME: 2 minutes]
Insights Into the Current and Future Treatment of Myasthenia Gravis
January 18th 2023James F. Howard Jr, MD, and Nicholas J. Silvestri, MD, FAAN, offer their experiences in treating patients with myasthenia gravis and their thoughts on the future of the care paradigm with novel agents in development.
